209 related articles for article (PubMed ID: 35220871)
1. Osilodrostat oral tablets for adults with Cushing's disease.
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
[TBL] [Abstract][Full Text] [Related]
2. Osilodrostat for the treatment of Cushing's disease.
Rasool S; Skinner BW
Expert Opin Pharmacother; 2021 Jun; 22(9):1099-1106. PubMed ID: 33703978
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M; Tritos NA
Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
Fleseriu M; Biller BMK
Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
[TBL] [Abstract][Full Text] [Related]
7. Osilodrostat for Cushing Disease and Its Role in Pediatrics.
Groselj U; Sikonja J; Battelino T
Horm Res Paediatr; 2023; 96(6):573-580. PubMed ID: 35045421
[TBL] [Abstract][Full Text] [Related]
8. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
9. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.
Ferriere A; Salenave S; Puerto M; Young J; Tabarin A
Eur J Endocrinol; 2024 Jan; 190(1):L1-L3. PubMed ID: 38123490
[TBL] [Abstract][Full Text] [Related]
10. Osilodrostat: A Review of Recent Clinical Studies and Practical Recommendations for its Use in the Treatment of Cushing Disease.
Yuen KCJ
Endocr Pract; 2021 Sep; 27(9):956-965. PubMed ID: 34389514
[TBL] [Abstract][Full Text] [Related]
11. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
Dougherty JA; Desai DS; Herrera JB
Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
[TBL] [Abstract][Full Text] [Related]
12. Osilodrostat - an emerging drug for the medical management of Cushing's disease.
Witek P; Mehlich A; Stasiewicz A; Jawiarczyk-Przybyłowska A; Bolanowski M
Endokrynol Pol; 2022; 73(2):371-374. PubMed ID: 35381096
[TBL] [Abstract][Full Text] [Related]
13. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
[TBL] [Abstract][Full Text] [Related]
14. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
Paton DP
Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
[TBL] [Abstract][Full Text] [Related]
15. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
[TBL] [Abstract][Full Text] [Related]
16. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
[TBL] [Abstract][Full Text] [Related]
17. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
18. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
Fleseriu M; Newell-Price J; Pivonello R; Shimatsu A; Auchus RJ; Scaroni C; Belaya Z; Feelders RA; Vila G; Houde G; Walia R; Izquierdo M; Roughton M; Pedroncelli AM; Biller BMK
Eur J Endocrinol; 2022 Oct; 187(4):531-541. PubMed ID: 35980235
[TBL] [Abstract][Full Text] [Related]
20. Osilodrostat: First Approval.
Duggan S
Drugs; 2020 Apr; 80(5):495-500. PubMed ID: 32141023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
